Table II.
Clinical trial information on various small molecule inhibitors.
| Small-molecule inhibitor | Clinical phase (clinical trial no.) | Disease |
|---|---|---|
| SY-1365 | Phase 1 (NCT03134638) | Ovarian cancer, breast cancer, advanced solid tumors |
| OTX015 | Phase 1 (NCT01713582) | Acute myeloid leukemia |
| OTX015 | Phase 1 (NCT01713582) | Diffuse large B-cell lymphoma |
| OTX015 | Phase 1 (NCT01713582) | Acute lymphoblastic leukemia |
| OTX015 | Phase 1 (NCT01713582) | Multiple myeloma |
| OTX015 | Phase 1 (NCT02259114) | NUT midline carcinoma |
| OTX015 | Phase 1 (NCT02259114) | Triple negative breast cancer |
| OTX015 | Phase 1 (NCT02259114) | Non-small cell lung cancer with rearranged ALK gene/fusion protein or KRAS mutation |
| OTX015 | Phase 1 (NCT02259114) | Castrate-resistant prostate cancer |
| OTX015 | Phase 1 (NCT02259114) | Castration-resistant prostate cancer |
| OTX015 | Phase 1 (NCT02259114) | Pancreatic ductal adenocarcinoma |
| OTX015 | Phase 2 (NCT02296476) | Glioblastoma multiforme |
| OTX015 | Phase 1 Phase 2 (NCT02303782) | Acute myeloid leukemia |
| OTX015 | Phase 1 (NCT02698176) | NUT midline carcinoma |
| OTX015 | Phase 1 (NCT02698176) | Triple negative breast cancer |
| OTX015 | Phase 1 (NCT02698176) | Non-small cell lung cancer |
| OTX015 | Phase 1 (NCT02698176) | Castration-resistant prostate cancer |
| CPI0610 | Phase 2 (NCT02986919) | Peripheral nerve tumors |
| CPI0610 | Phase 1 (NCT01949883) | Lymphoma |
| CPI0610 | Phase 1 (NCT02157636) | Multiple myeloma |
| CPI0610 | Phase 2 (NCT02158858) | Leukemia, myelocytic, acute |
| LEE011 | Phase 2 (NCT02934568) | Advanced cancer, advanced solid tumors |